Indeed, in vitro kinase assays using purified components and 10 μM ATP showed that CRAF efficiently phosphorylates purified CDK4 at T172, whereas CDK7 and c-Jun N-terminal kinase (JNK) were excluded as relevant CAKs in the context of NF1-depleted ER+ breast cancer. The gene discussed is NF1; the disease is breast carcinoma.